Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study
Akhtar et al.
, Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study
, The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634
Retrospective 423 patients in Pakistan, 216 receiving 6 day treatment, showing lower mortality, lower ICU admission, and faster viral clearance with treatment. Limited baseline information per group is provided. There were more severe patients in the ivermectin group. Logistic regression results are mentioned without full details. The difference in mortality was not statistically significant in logistic regression.
This study is excluded in meta
pending additional information from authors.
risk of death, 90.4% lower, RR 0.10, p < 0.001, treatment 2 of 216 (0.9%), control 20 of 207 (9.7%), NNT 11.
risk of ICU admission, 71.6% lower, RR 0.28, p < 0.001, treatment 8 of 216 (3.7%), control 27 of 207 (13.0%), NNT 11.
risk of no hospital discharge, 79.6% lower, RR 0.20, p < 0.001, treatment 10 of 216 (4.6%), control 47 of 207 (22.7%), NNT 5.5.
time to viral-, 58.8% lower, relative time 0.41, p < 0.001, treatment mean 8.39 (±2.04) n=216, control mean 20.38 (±6.32) n=207.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Akhtar et al., 1 Sep 2022, retrospective, Pakistan, peer-reviewed, mean age 51.9, 9 authors, dosage 12mg days 1-6.
Abstract: COVID-19 Mortality and Ivermectin
The Professional Medical Journal
2022, Volume, 29 Issue, 09
Does ivermectin reduce COVID-19 mortality and progression of disease severity?
– A retrospective study.
Tehseen Akhtar1, Amber Hanif2, Pyar Ali3, Muhammad Hussain Haroon4, Nimra Akram5, Muhammad Umar Raza6, Khalid Imran7,
Nimra Shakeel8, Ramsha Shakeel9
Article Citation: Akhtar T, Hanif A, Ali P, Haroon MH, Akram N, Raza MU, Shakeel N, Shakeel R. Does ivermectin reduce COVID-19 mortality
and progression of disease severity? – A retrospective study. Professional Med J 2022; 29(9):1384-1391.
ABSTRACT… Objective: To investigate the efficacy of ivermectin in the treatment of mild, moderate, and severe COVID-19
infection. Study Design: Retrospective Cohort study. Setting: COVID-19 Treatment Centre, Dr. Ruth K M Pfau Civil Hospital
Karachi. Period: July 2020 to December 2020. Material & Methods: Medical records of 423 patients during a selected
duration of 6 months were reviewed. Patients were stratified into two groups based on whether or not they received a 6-day
course of ivermectin in addition to the standard treatment for COVID-19. Primary outcome measures were rate of mortality,
days from the start of treatment to negative SARS-CoV-2 PCR, and rate of step-up to the intensive care unit. Results: Patients
who received ivermectin required a lesser number of days (8.39 days ± 2.04) to become COVID negative than the patients
who didn’t receive ivermectin (20.38 days ± 6.32), (p < 0.001). Multinomial logistic regression showed that the patients who
were given ivermectin for COVID 19 infection were four times more likely to be discharged home than stepping up to ICU.
The ICU step-up rate in the ivermectin group was found to be 3.7% compared to 13.04% in the non-ivermectin group. No
significant differences in mortality were found. Conclusion: Treatment with ivermectin in COVID-19 infection is associated
with improved outcomes in terms of reduction in duration of illness as well as the progression of disease severity.
Ivermectin, COVID-19, SARS-CoV-2, Mortality.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.